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Abstract Current guidelines and literature on
screening for coronary artery calcium for cardiac risk
assessment are reviewed for both general and special
populations. It is shown that for both general and
special populations a zero score excludes most clini-
cally relevant coronary artery disease. The importance
of standardization of coronary artery calcium mea-
surements by multi-detector CT is discussed.
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Introduction
In 1996 and 2000, the American Heart Association
(AHA) issued statements on coronary artery calcium
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DOI 10.1007/s10554-008-9319-z(CAC) quantiﬁcation [1, 2]. In 2006 and 2007, several
professional societies updated these statements
describing new evidence related to CAC imaging [3–
5]. The purpose of the present work is to summarize
the rationale and content of those recommendations
with regard to CAC quantiﬁcation, to address differ-
ences among them and to point out controversial areas
ofCACresearchofhighclinicalrelevanceamongboth
asymptomatic and symptomatic persons.
Nearly all of the published clinical outcome data
from CAC are based on results obtained with electron
beam tomography (EBT) systems. However, these CT
systems are largely no longer available and are being
widely replaced with multi-detector CT (MDCT)
systems. EBT, produced by one manufacturer, pro-
videdmuchmorestandardizationthanexistsforallthe
various generations of MDCT systems from different
manufacturers. Standardization guidelines have been
proposed for MDCT [6], but are rarely used. Studies
with earlier MDCT technology (4–16 slice) have
demonstrated that similar mean CAC scores can be
obtained with EBT and MDCT [7–12]. Nevertheless
systematic differences exist which can likely affect
serial measurements [6, 13, 14].
While large numbers of patients were included in
the EBT outcome studies, most of these suffered from
selection biases related to ethnicity, patient self-
referral or referral by physicians concerned about
subclinical coronary artery disease (CAD) due to the
presence of risk factors. The Dallas Heart Study [15],
Multi-Ethnic Study of Atherosclerosis (MESA) [16],
and Rotterdam Study [17, 18] have attempted to
address some of these issues. The results from
general populations cannot reliably be applied to
special populations. Nevertheless it is clear from
many studies that in all kinds of populations, even in
high-risk populations such as diabetic patients, and in
both symptomatic and asymptomatic patients, the
absence of coronary artery calcium (zero calcium
score) excludes most clinically relevant CAD. This
information is highly relevant since many individuals
of subjects among the general as well as special
populations have a zero calcium score.
In this paper, we review the evidence in support of
the use of CAC for cardiac risk assessment in the
general population as well as special populations with
particular focus on the importance of a zero score.
The need for standardization of CAC measurements
with MDCT is also discussed.
Coronary artery calcium as a predictor
of cardiac events
Most published studies addressing the issue of coro-
nary artery calcium as a predictor of cardiac events are
based on EBT data. In the ACCF/AHA Consensus
Document on Coronary Artery Calcium Scoring 6
such studies were selected for review because they
fulﬁlled sufﬁcient criteria for outcome analysis [18–
23]. From the data presented in these studies, it was
concluded that coronary artery calcium scores add
incremental prognostic value in the evaluation of
patients at intermediate risk for a coronary event.
Other studies further support this conclusion. Raggi
et al. [24] screened 632 asymptomatic patients with
EBT and followed them for 32 months to determine
the incidence of hard cardiac events (myocardial
infarction, MI and death). The majority of events
occurred in individuals with high calcium scores and
in individuals with scores[75th percentile compared
with age and sex matched controls. Arad et al. [19]
screened 1,172 asymptomatic patients with EBT and
followed them for a mean of 3.6 years to determine
the incidence of cardiovascular end points (MI, death
and the need for revascularization). The authors
concluded that in asymptomatic adults EBT calcium
scores are highly predictive of events. Pletcher et al.
[25] conducted a meta-analysis of studies performed
between 1980 and 2003 in * 13,000 asymptomatic
patients screened with EBT and followed for 3.6 years
or less to determine the odd ratios (OR) of hard
coronary events. OR for Agatston CAC scpres\100,
100–400 and[400 were 2.1, 4.2 and 7.2, respec-
tively. The authors concluded that the EBT derived
Agatston calcium score is an independent predictor of
coronary events in asymptomatic subjects.
CAC as an indicator of coronary artery
luminal stenosis
Only studies based on EBT data have addressed the
issueofCACasanindicatorofcoronaryarteryluminal
stenosis. Haberl et al. [26] analyzed the value of EBT
derived calcium CAC scores as an indicator of
coronary luminal stenoses in 1,764 patients undergo-
ing conventional coronary angiography. The authors
concluded that EBT CAC scores are highly sensitive
but moderately speciﬁc determinants of stenosis. The
646 Int J Cardiovasc Imaging (2008) 24:645–671
123ACC/AHA Expert Consensus Document on Electron-
Beam CT for the diagnosis and prognosis of CAD [1]
reported a pooled sensitivity of 91.8% and speciﬁcity
of 55% for detection of a coronary artery stenosis[
50% after reviewing 16 selected studies comparing
CACscoresandinvasiveangiography.Knezet al.[27]
compared EBT derived Agatston CAC scores with
calcium volume scores (CVS) as a predictor of
coronary luminal stenoses in 2,115 patients undergo-
ing conventional coronary angiography. The authors
reported overall results similar to those already
reported by others, but also concluded that the CVS
are as accurate as the Agatston score for stenosis
prediction. Indeed, Budoff et al. [28] utilized CVS
obtained by EBT to predict the presence of coronary
artery stenoses in 1,851 patients undergoing conven-
tional coronary angiography and concluded that CVS
provide incremental value in predicting the severity
and extent of angiographically signiﬁcant CAD.
Clinical comparison of MDCT and EBT for
coronary artery calcium score measurement
Knez et al. [12] studied 99 symptomatic men (mean
age: 60 years) with both MDCT (prospective trigger-
ing, Siemens Volume Zoom) and EBT imaging and
foundacorrelationcoefﬁcientof0.99forCVSand0.98
for the mass score (MS) with a mean overall variability
of 17%. No signiﬁcant differences for scores 1–100,
101–400, 401–1000,[1000 were found. The authors
concluded that MDCT is equivalent to EBT for CAC
scoring. Becker et al. [7] compared a 4-slice MDCT
(Siemens Volume Zoom) with EBT (prospective trig-
gering) in 100 patients and calculated the Agatston
score, CVS and MS. The authors concluded that the
scorevariabilityishighestfortheAgatstonscore(32%)
and the correlation between MSCT and EBT is
excellent for CVS and MS. Carr et al. [8]p e r f o r m e d
CT examinations with both GE Lightspeed LX/i
4-slice MDCT (retrospective gating) and EBT in 36
patientsandcalculatedtheAgatstonscoreinallofthem.
The authors reported excellent correlation between
scores obtained on the 2 CT systems. Horiguchi et al.
[11] performed EBT and 16-MDCT with retrospective
gating in 100 patients and reported a high degree of
correlation between the 2 CT systems for the Agatston
score (r
2 = 0.955), CVS (r
2 = 0.952) and MS
(r
2 = 0.977). Daniell et al. [9] compared the results of
EBT and 4-slice MDCT (prospective triggering, Sie-
mens Volume Zoom) in 68 patients. EBT and MDCT
scores correlated well (r = 0.98–0.99) with a median
variability between EBT and MDCT for the Agatston
score of * 25% and * 16% for CVS. Scores were
higher for EBT than MDCT in approximately half of
the cases, with little systematic difference between the
two (median EBT-MDCT difference: Agatston score,
-0.55; volume score, 3.4 mm
3).
Review of current guidelines on coronary artery
calciﬁcation
Risk assessment in asymptomatic persons
Risk stratiﬁcation algorithms such as the Framingham
risk score (FRS) [29], the PROCAM score [30] or the
European SCORE-system [31, 32] are used to assess
an individual’s global 10-year risk. Risk factors are
measured and weighed and attributed to an empiri-
cally determined absolute risk of cardiovascular
events, i.e. cardiac death and MI [33]:
– low risk B 1% per year or\10% in 10 years
– intermediate risk = 1 - 2% per year or 10–20%
in 10 years
– high risk C 2% per year or[20% in 10 years.
This classiﬁcation was slightly modiﬁed by the
2004 update of NCEP guidelines (Table 1)[ 34].
It is argued that persons at high risk will most
likely beneﬁt from intensive risk modiﬁcation, while
persons at low risk are generally recommended to
adhere to a healthy lifestyle and guideline-based
treatment of individual risk factors when present. In
persons at intermediate risk, however, there remains a
diagnostic gap and further tests, such as CAC scoring,
measuring intima-media thickness (IMT), the ankle
arm index, or exercise stress testing may be useful in
distinguishing individuals who indeed have a high
risk from those at low risk, leaving hopefully few that
remain at intermediate risk [33]. It should be
recognized, though, that the Framingham score does
not take into account life-style factors such as diet,
exercise and body mass index. Neither does the score
reﬂect a positive family history of cardiovascular
disease. The extent of atherosclerotic disease burden,
autonomic dysfunction, chronic inﬂammation, lipo-
protein subfractions, blood thrombogenicity, the
Int J Cardiovasc Imaging (2008) 24:645–671 647
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arrhythmias, and immeasurable genetic factors are
also not part of conventional risk assessment. Mea-
suring the atherosclerotic sequelae of life-long global
exposure to all risk factors by virtue of measuring the
extent of the disease in its early subclinical stages
may overcome this limitation. The detection of
calciﬁed atherosclerosis is a general surrogate of
total atheroma burden. It is noted however, that the
extent of coronary calciﬁcation systematically differs
among ethnic populations and by gender.
The focus of current guidelines on CAC scoring
The AHA Scientiﬁc Statement on ‘‘Assessment of
CoronaryArteryDisease(CAD)byCardiacComputed
Tomography’’ [3] reviewed scientiﬁc data for cardiac
CT related to imaging of CAD and atherosclerosis in
symptomatic and asymptomatic subjects, including a
detailed description of technical aspects and radiation
exposure of CAC CT and non-invasive CT angiogra-
phy using EBT and MDCT. According to AHA
standards, recommendations were classiﬁed (Class I,
IIa, IIb and III) and the level of evidence (A, B, or C)
was provided (see http://circ.ahajournals.org/manual/
manual_IIstep6.shtml).
The ACC/AHA 2007 Clinical Expert Consensus
Document[4]discussedtheroleofCACquantiﬁcation
with respect to (1) identifyingand modifying coronary
event risk in asymptomatic subjects, (2) modifying
clinical care and outcomes of symptomatic patients
with suspected CAD and (3) understanding the role of
CAC CT in selected patient sub-groups, including
women, ethnic groups, and patients with renal disease
or diabetes. (4) The clinical value of serial CAC CT,
cost-effectiveness of CAC CT, and clinical implica-
tions of incidental ﬁndings were also addressed.
The purpose of the 2006 Appropriateness Criteria
Statement [5] was to create, review and categorize
appropriateness criteria for cardiac CT and also
cardiac magnetic resonance imaging (MRI) with
regard to detection of CAD, cardiovascular risk
stratiﬁcation, as well as cardiac structure and function
assessment. Members of the expert group assessed
the risks and beneﬁts of the imaging tests for several
indications and clinical scenarios and scored them
based on a scale of 1–9:
7–9 = appropriate: the test is generally acceptable
and is a reasonable approach
4–6 = uncertain: uncertain indication or clinical
setting
1–3 = inappropriate: the test is generally not
acceptable/is not a reasonable approach
Indicationsinthelatterstatementwerederivedfrom
commonapplicationsoranticipatedusesofcardiacCT
and MRI. Working group panelists rated each indica-
tionbasedontheACCMethodologyforEvaluatingthe
Appropriateness of Cardiovascular Imaging [35].
Indications for CAC scoring in asymptomatic
individuals
In the past several years, numerous publications have
reported on the incremental prognostic value of CAC
over measured conventional risk factors in large series
of patients including asymptomatic population-based
cohorts [18, 20–23, 36]. The relative risk of coronary
events increased with increasing CAC burden (Fig. 1).
Table 1 Absolute risk categories ‘‘NCEP-Update 2004’’, modiﬁed from [34]
Ten-year risk categories Deﬁnition of risk category
High risk CAD
a, CAD-risk equivalents
b, C 2 major risk factors
c, 10-year-risk[20%
Moderately high risk C2 major risk factors but 10-year CAD risk 10–20%
Moderate risk C2 major risk factors but 10-year CAD risk\10%
Low risk 0–1 major risk factor and 10-year CAD risk\10%
CAD: coronary artery disease
a History of myocardial infarction, coronary revascularisations or myocardial ischemia
b Includes diabetes mellitus, stroke, TIA or carotid artery stenosis[50%, symptomatic peripheral artery disease or abdominal
aortic aneurysm
c Smoking, hypertension, high LDL-cholesterol/low HDL-cholesterol, age (men[45 years., women[55 years), and premature
family history of CAD (ﬁrst grade family member, i.e. men\55 years., women\65 years)
648 Int J Cardiovasc Imaging (2008) 24:645–671
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it may be reasonable to consider use of CAC measure-
ment in asymptomatic intermediate risk patients, i.e.
10–20% coronary events in 10 years. These patients
might be reclassiﬁed to a higher risk status based on a
high CAC score, and subsequent patient management
may be modiﬁed (Fig. 2). In the ACC Appropriateness
Criteria Document, notably published prior to the most
recent AHA and ACC statements and additional
prospective CAC scoring studies, CAC scoring was
considered appropriate only for very few indications.
However,allofthemweregivenaratingof‘‘uncertain’’,
most notably CAC scoring for risk assessment in the
general population at moderate (score 6) or high (score
5) CAD Framingham risk. In patients with a low or a
high 10 year risk of coronary events, i.e.\10%
or[20% in 10 years, CAC quantiﬁcation is not
recommended: in low risk individuals, even a high
CAC score does not generally elevate this person’s risk
abovethethresholdtoinitiatetherapy[4].Yet,life-time
risk may be elevated in 18% and 20% of asymptomatic
men and women, respectively, who have a high CAC
score, i.e. CAC[400 or[75th percentile, despite a
low FRS [37]. Persons with a high 10-year risk are
candidates for intensive risk modiﬁcation based on
current NCEP guidelines [34], and there is no evidence
that a low CAC score substantially reduces this risk.
This also holds for persons with risk equivalents. The
performance of serial (follow-up) calcium scoring
examinations was not recommended.
Atherosclerotic disease quantiﬁcation in patients
with chest pain
In symptomatic patients, diagnostic tests may be used
for risk stratiﬁcation, but the primary initial objective
is to identify or rule out obstructive CAD. Especially
in young persons with atypical chest pain, non-
atherosclerotic non-obstructive coronary disease such
as myocardial bridging, coronary anomalies, coro-
nary vasospasm, intramyocardial small vessel
disease, or non-coronary heart disease (CHD) such
as cardiomyopathy, valvular heart disease, pericardial
disease, aortic disease, pulmonary disease, etc. must
be considered as differential diagnoses. Persons with
an intermediate pretest-likelihood of obstructive
CAD, i.e. between 20 and 80%, are most likely to
beneﬁt from additional testing [38].
Functional tests such as treadmill, exercise or
pharmacological nuclear stress tests or stress-echo-
cardiography are used to induce myocardial ischemia
in patients with ﬂow limiting coronary obstruction. In
contrast, CAC CT is aimed at estimating coronary
plaque severity and the associated likelihood of a
ﬂow-limiting lesion. These two approaches, the
former functional and the latter morphological, are
distinctly different and have inherently different
reasons for false positive and false negative results.
The presence of CAC is almost 100% sensitive for
thepresenceofatheroscleroticcoronaryplaquebutnot
speciﬁc for ﬂow limiting plaque, as both obstructive
andnon-obstructivelesionscancontaincalciﬁcdepos-
its in the vessel wall. However, increasing calcium
scores are associated with an increasing likelihood of
both obstructive disease, and an increased severity
Fig. 1 Increase in relative risk (RR) with increasing CAC
scores in asymptomatic persons in comparison to asymptom-
atic persons without CAC (modiﬁed from [20])
Fig. 2 Annual rate of myocardial infarction or cardiac death in
categories of CAC burden in persons at intermediate risk based
on convention risk factor assessment. In persons with a high
CAC score ([400), the annual event rate exceeds the threshold
for intensive risk factor modiﬁcation, i.e.[2% per year (black
line). A CAC score[400 in intermediate risk persons may
thereforebeconsideredasariskequivalent(modiﬁedfrom[20])
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coronary calcium scores (approximately 150) in
symptomatic patients are associated with a roughly
80% sensitivity and speciﬁcity for the presence of an
obstructive coronary artery lesion (among patients
referredtocoronaryangiography)[26,28]anaccuracy
that is similar in magnitude to conventional stress tests
[38, 39]. Consistent with these data are ﬁndings from
myocardialperfusionscintigraphyinwhichonly2%of
patientswithaCACscore\100wereshowntohavea
positive nuclear stress test [40]. A clinical application
of these relationships has been demonstrated among
emergency department patients with chest pain, in
whom a zero calcium score was associated with a very
low risk of cardiovascular events [41]. Caution in the
interpretation of zero calcium scores is warranted
among individuals with a high pretest probability for
CAD (e.g., young smokers) in whom false negative
studies may be observed [42].
In summary, the majority of expert writing com-
mittee members agreed that patients at low risk of
CAD by virtue of atypical cardiac symptoms may
beneﬁt from CAC testing to help exclude the
presence of obstructive CAD. CAC scoring may be
a useful ﬁlter prior to invasive angiography or further
stress testing [43, 44]. However, more data on direct
comparisons with established forms of stress testing
are needed. Currently, additional non-invasive testing
in persons with a very high CAC score, e.g.[400 is
not recommended as there is no evidence that such
additional testing will improve appropriate selection
of candidates for therapy. CAC CT was classiﬁed as
‘‘Class IIb, Level of Evidence: B’’ when used to rule
out obstructive CAD in patients with chest pain with
equivocal or normal ECGs and negative cardiac
enzymes, and in symptomatic patients in the setting
of equivocal exercise stress tests [3].
Other clinical scenarios: Serial imaging of CAC to
assess disease progression is currently not indicated
by the existing guidelines [3]; this issue is discussed
later herein. Existing evidence on CAC CT has
mostly been gathered from studies in Caucasian men
and caution is warranted in extrapolating existing
data to other ethnic groups or women.
Implications for therapy
The NCEP/ATP III Guidelines have incorporated
CAC CT as a complementary test to modify
treatment intensity: ‘‘Measurement of coronary cal-
cium is an option for advanced risk assessment in
appropriately selected persons. In persons with
multiple risk factors, high coronary calcium scores
(e.g.,[75th percentile for age and sex) denote
advanced coronary atherosclerosis and provide a
rationale for intensiﬁed LDL-lowering therapy.
Moreover, measurement of coronary calcium is
promising for older persons in whom the traditional
risk factors lose some of their predictive power [34].
The use of CAC percentile ranks, as advocated in the
NCEP guidelines, is especially important in young
individuals whose absolute scores may be low, yet
‘‘high-for-age’’, indicating a high life-long risk, even
though short-term risk over the next 5–10 years may
be low. As risk factor modiﬁcation in high-risk
subjects should be initiated as early as possible, such
persons are likely appropriate candidates for intensive
risk modiﬁcation—a notion that needs to be further
conﬁrmed by prospectively collected outcome data.
Limitations
There is currently little evidence that CAC CT and
knowledge of CAC score severity has an impact on
the advice physicians give to patients or on patients’
adherence to prescribed risk factor modiﬁcation
efforts [45]. Further, CAC CT may improve risk
stratiﬁcation in selected populations, but currently the
data are limited that CAC CT improves outcome.
Accordingly, current evidence does not support
lowering treatment intensity in intermediate risk
subjects even if the CAC score is zero [4].
Summary
Current guidelines propose the use of CAC CT to
improve risk stratiﬁcation in subjects at intermediate
10-year risk of incident coronary events. The present
writing committee agrees with this general
recommendation.
Race and calcium score
There is still limited knowledge of the predictive
value of CAC in non-Caucasians. It has been well
documented that there is a notable difference in CAC
accumulation not only between men and women, but
650 Int J Cardiovasc Imaging (2008) 24:645–671
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races. Doherty et al. [46] using subtraction ﬂuoros-
copy ﬁrst noted a signiﬁcantly lower prevalence of
CAC in Blacks than Whites (35.5 vs. 59.9%,
P = 0.0001) and warned of the different prognostic
signiﬁcance of CAC in these races. Indeed, during a
follow up of 70 ± 13 months, 23.7% of the black and
14.8% of the white screened population suffered an
incident cardiovascular event (odds ratio: 2.16, 95%
CI: 1.34–3.48). The signiﬁcant difference in preva-
lence and distribution of CAC assessed by CT in 4
races in the US, was recently conﬁrmed by the Multi-
Ethnic Study of Atherosclerosis. Bild et al. [16]
showed that the prevalence of CAC on cardiac CT
(score[0) was highest in Whites followed by
Chinese, Hispanics and ﬁnally Blacks. Santos et al.
[47] showed that North American Caucasian subjects
have more CAC than Caucasian subjects from Brazil
and Portugal despite the higher prevalence of risk
factors in the latter two ethnic groups. Interestingly,
despite a substantial genetic similarity between
Brazilian and Portuguese patients, and the presence
of more smokers among the latter, Brazilians had a
greater extent of coronary artery calcium than
Portuguese subjects. These ﬁndings mirrored the
national mortality and morbidity statistics indicating
a greater cardiovascular event rate in the North
American, followed by the Brazilian and ﬁnally the
Portuguese population.
Despite the noted differences in CAC scores, there
is currently limited evidence of the prognostic
signiﬁcance of CAC in different races. Detrano et al.
[48] showed that CAC is a strong predictor of
cardiovascular death, non-fatal MI, angina and
revascularization (total events = 162) in all 6,722
MESA patients independent of race. Furthermore,
CAC added incremental prognostic value beyond
traditional risk factors for the prediction of events.
Recently,Nasiret al.[49]evaluatedtheuseofCAC
to predict all-cause mortality in 14,812 patients
belonging to the same four races considered in MESA
(505 deaths in 10 years of follow-up). Once again the
prevalence of CAC was highest in Whites, although
Blacks and Hispanics had a greater clustering of risk
factors for CAD. Despite a lower prevalence of CAC
and lower scores compared to the other races, black
patients had the highest mortality rates even after
multivariable adjustment for clinical risk factors and
baseline CAC score (P\0.0001). Compared with
Whites, the relative risk of death was 2.97 (CI: 1.87–
4.72) in Blacks, 1.58 (CI: 0.92–2.71) in Hispanics and
0.85(CI:0.47–1.54)inChineseindividuals.A50-year-
old black patient with a CAC score[400 had an
estimated loss of 7 years of life, as opposed to
2.5 yearsoflifeforawhitepatientwiththesamescore.
Therefore, it would appear appropriate to consider
CAC a good marker of risk in all races so far
investigated, although the prognostic signiﬁcance of
score categories varies between racial groups. This
underscores the importance of racial speciﬁc risk
categories deﬁned according to CAC score thresh-
olds. An attempt at deﬁning such categories was
recently published by Sirineni et al. [50]. In their
publication the authors suggested substituting the
chronological age of a patient undergoing CAC
screening for his vascular age. The vascular age can
be assessed according to the median CAC score for a
subject of the same age, race and sex. For example a
50-year-old black man with a CAC score of 40 should
be considered * 20 years older than his chronolog-
ical age, since 40 is the median score of a 70-year-old
black man in MESA. On the other hand, a score of 40
adds only 11 years of age to a 50-year-old white man.
The prognostic validity of this novel approach is still
awaiting conﬁrmation in prospective studies.
The value of coronary artery calcium
in the elderly population
The assessment of coronary calciﬁcation may have
particular value in the elderly population. The
potential for prevention of CHD in older adults is
large, since even a small reduction in risk factor
levels results in a considerable reduction in event
rates. However, to identify asymptomatic elderly in
the population at the highest risk of CHD is
challenging. Ofﬁce-based risk score algorithms like
the FRS [29] and the European SCORE [31] have an
upper age threshold that limits their applicability to
older adults. Furthermore, the predictive power of
risk factors diminishes with increasing age [51–53].
Finally, age becomes the predominant factor in the
algorithm in older adults, despite the fact that a ﬁxed
weight attributed to age does not take into account the
individual variation in coronary plaque burden. On
the basis of risk factors and age, the true CHD risk
may be miscalculated, and this may lead to inaccurate
Int J Cardiovasc Imaging (2008) 24:645–671 651
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modiﬁcation.
CAC reﬂects the life-time impact of all athero-
sclerosis risk factors, both known and unknown, on
the arterial wall [54]. Thus, this non-invasive mea-
surement can provide a more accurate estimate of the
accumulated plaque burden and CHD risk. So far, one
population-based study has focused on the predictive
value of CAC in the elderly: the Rotterdam Coronary
Calciﬁcation Study (mean age, 71 years) [18]. During
a mean follow-up period of 3.3 years, 50 of the 1,795
initially asymptomatic subjects had a coronary event.
Increasing CAC score categories showed relative
risks for CHD up to 8.2 (95% CI: 3.3–20.5) for a
CAC score above 1,000, compared to absent or low
CAC score (0–100). Similar relative risks were found
after adjustment for risk factors and in asymptomatic
individuals over 70 years of age. Of interest, there
was a very low probability of events in subjects with
a low CAC score (0–100). Furthermore, irrespective
of the Framingham risk category (low-to-intermedi-
ate or high risk), increasing CAC score categories
were strongly associated with the risk of events.
Thus, a low CAC score in elderly may be as valuable
a ﬁnding as in younger subjects. These results
indicate that the CAC score is a very promising
measurement to improve cardiovascular risk stratiﬁ-
cation in the elderly. In a recent publication, Abbott
et al. [55] reported on 224 very old (age 84–96)
Japanese men living in Hawaii followed for an
average of 2.5 years after CAC imaging. A total of 17
deaths occurred during 2.5 years of follow-up and no
death occurred in patients with a CAC score\10. As
shown in the study by Vliegenthart et al. [18], the
death rate increased signiﬁcantly as the CAC score
increased (P\0.001). Finally, Newman et al. [56]
measured CAC and carotid IMT in 559 patients (336
women) age 70–99 years. The top quartile of each
measurement was associated with * 2-fold
increased risk of a combined cardiovascular disease
end-point.
Other population prospective studies have been
conducted in a wide age range [20–22, 24, 36, 57].
Most of these studies did not speciﬁcally address the
predictive value of CAC in older age. In a study by
LaMonte et al. [22], CHD event rates adjusted for
gender were presented in different age groups. In
subjects over 65 years of age, a graded increase in
event rates was seen for CAC scores C 100
and C 400 (7.1 and 8.2 per 1000 person-years,
respectively). Conversely, absence of CAC was
associated with a very low event rate (0.9 per 1,000
person-years).
Summary
These data support the notion that CAC screening
may be used in all age groups to adjust the relative
risk level. They must, however, be considered
preliminary; more research will be needed to dem-
onstrate that expensive medical therapies can be
withheld in the elderly with risk factors in the
absence of CAC and to establish the best approach to
managing older, asymptomatic patients with exten-
sive CAC.
Diabetes mellitus and coronary artery calcium
Patients suffering from diabetes type–2 have been
shown to harbor larger amounts of CAC than non-
diabetic patients with the metabolic syndrome [58]
and subjects of similar age and otherwise similar risk
factor proﬁle [58, 59]. The extent of CAC in patients
with type-2 diabetes is similar to that of patients with
established CAD but without diabetes, diabetic
women harbor as much CAC as diabetic men [60,
61], and younger diabetic individuals have a plaque
burden comparable to that of older non-diabetic
individuals [62]. All of this conﬁrms the clinical
evidence that diabetes mellitus is associated with a
very high prevalence of CAD; it negates the advan-
tage of women over men and of youth over older age
in prevalence and extent of atherosclerosis. Hoff
et al. utilized a large database to calculate the age and
gender normative (percentile) distribution of calcium
scores in asymptomatic (self-reported) diabetic indi-
viduals [62].
Olson et al. [63] investigated the presence of CAC
and prior CAD in 302 patients with diabetes mellitus
type-1 and a history of MI, angina, or evidence of
ischemia on stress testing or surface electrocardio-
grams. Among the subjects free of clinical CAD, 5%
had a CAC score C 400 (large atherosclerosis bur-
den), as opposed to 25% of the subjects with prior
angina or objective evidence of myocardial ischemia
and 80% of the patients with MI or luminal stenoses
on invasive angiography. CAC showed a sensitivity
652 Int J Cardiovasc Imaging (2008) 24:645–671
123of 84% and 71% for clinical CAD in men and
women, respectively, and 100% sensitivity for MI
and obstructive CAD.
Limited data exist on outcome related to CAC in
diabetic patients. Wong et al. [64] performed CAC
screening and stress myocardial perfusion imaging
(MPI) in 1043 patients, 313 of whom were affected
by either diabetes mellitus (N = 140) or the meta-
bolic syndrome (N = 173). In patients with a CAC
score\100, the prevalence of stress induced MPI
abnormalities was very low (* 2%). However, in the
presence of a metabolic disorder (diabetes mellitus or
the metabolic syndrome) a CAC score between 100
and 399 or greater than 400 was associated with a
greater incidence of ischemia than in patients without
a metabolic disorder (13% vs. 3.6%, P\0.02, and
23.4% vs. 13.6%, P = 0.03, respectively). Similarly,
Anand et al. [65] performed sequential CAC screen-
ing and MPI in 180 type-2 diabetic patients. The
incidence of myocardial ischemia was directly pro-
portional to the CAC score. For type-2 diabetic
patients with a CAC score of 0, 11–100, 101–400,
401–1,000, and[1,000, the incidence of myocardial
ischemia on stress MPI was 0%, 18%, 23%, 48%, and
71%, respectively. In summary, based on the Wong
[64] and Anand data [65], type-2 diabetic patients
with a CAC score[100 are expected to have an
increased frequency of ischemia on MPI.
Two outcome studies addressed the question of
whether CAC constitutes a risk for events in asymp-
tomatic patients but came to opposite conclusions.
The South Bay Heart Watch (SBHW) was a
prospective cohort study designed to determine the
relation between radiographically detectable CAC
and cardiovascular outcome in high-risk asymptom-
atic adults [66]. Thirteen hundred and twelve
asymptomatic subjects C 45 years old with cardiac
risk factors were recruited via mass-mailing adver-
tisement in the Los Angeles area; of these 19% were
diabetic patients. In a sub-analysis of the main
database after a mean follow-up of 6 years, Qu et al.
[66] found an increased risk of cardiovascular events
(death, MI, stroke and revascularizations) in diabetic
patients compared to non-diabetic subjects in the
presence of CAC. However, the risk did not increase
signiﬁcantly as the CAC score increased. Raggi et al.
[67] utilized a database of 10,377 asymptomatic
individuals (903 diabetic patients), followed for an
average of 5 years after CAC screening. The primary
end-point of the study was all-cause mortality. The
authors showed that the risk of all-cause mortality
was higher in diabetic patients than non-diabetic
subjects for any degree of CAC and the risk increased
as the score increased. Additionally, the absence of
CAC predicted a low short-term risk of death (* 1%
at 5 years) for both diabetic patients and non-diabetic
subjects [67]. Hence, both the presence and absence
of CAC were important modiﬁers of risk even in the
presence of established risk factors for atherosclerosis
such as diabetes mellitus. This suggests that there is a
great heterogeneity among diabetes mellitus patients
and that risk stratiﬁcation may be of beneﬁt even in
patients considered to be at high-risk of atheroscle-
rosis complications.
Summary
The preceding discussion suggests that CAC imaging
techniques may be very helpful to the practicing
physician faced with the dilemma of accurate risk
assessment even in diabetic patients at high risk.
However, as is the case with other subsets of patients,
further research will be needed to conﬁrm the
prognostic role of CAC in diabetes mellitus.
Renal failure and coronary artery calcium
Both EBCT and MSCT have been utilized in the
recent past to investigate the natural history and
pathogenesis of CAC, as well as the impact of
different therapeutic strategies in chronic kidney
disease (CKD). Evidence indicates that as the
estimated glomerular ﬁltration rate (eGFR) declines
the prevalence of CAC increases. In fact, the
prevalence of CAC was reported to be 40% in 85
pre-dialysis patients as opposed to 13% in controls
with normal renal function [68]. In a prospective
study of 313 high-risk hypertensive patients a
reduced eGFR was shown to be the major determi-
nant of the rate of progression of CAC (ORs for
calcium progression in the group with
eGFR B 60 ml/min: 2.1; 95% CI: 1.2–3.7) [69].
Consistent with these ﬁndings, Sigrist et al. [70]
reported a prevalence of CAC of 46% in 46 pre-
dialysis patients compared to 70% and 73% respec-
tively in 60 hemodialysis and 28 peritoneal dialysis
patients (P = 0.02). Hence, it appears that the
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function and after initiation of dialysis. Of note, CAC
was reported in * 60% of patients new to hemod-
ialysis [71] and in as many as 80–85% of adult
prevalent hemodialysis patients [72] in two prospec-
tive, randomized studies. In a small longitudinal
study, the baseline CAC score measured by EBT in
49 prevalent hemodialysis patients was on average 2-
to 5-fold higher than in age and sex matched
individuals with established CAD. A repeat CT after
an interval of 12 months showed signiﬁcant progres-
sion of CAC (P\0.05) [73].
A number of factors have been associated with
progression of CAC in dialysis patients. Associations
with age and duration of dialysis [72, 74], diabetes
mellitus [72] abnormalities of mineral metabolism
[75–77] as well as use and dose of calcium based
phosphate binders [78, 79] have all been reported. To
investigate the impact of therapy for hyperphosphate-
mia on the progression of CAC a randomized clinical
trial compared the effect of Sevelamer (Genzyme,
Cambridge, MA USA—a non-absorbable polymer
with gut phosphate binding ability) and calcium-based
phosphate binders in 200 hemodialysis patients for
1 year [78]. Throughout the study both drugs provided
a comparable phosphate control (mean phos-
phate = 5.1 mg/dl), although a signiﬁcantly higher
serumcalciumconcentration(P = 0.002)wasnotedin
the calcium-salts treated arm. At study completion
Sevelamer treated subjects were less likely to experi-
ence CAC progression (median absolute progression
ofCACscore0vs.36.6,P = 0.03andaorta0vs.75.1,
P = 0.01, respectively) [78].
In a smaller series of 129 patients new to
hemodialysis [80], subjects treated with calcium-
containing phosphate binders showed a more rapid
and more severe increase in CAC score compared
with those receiving Sevelamer (P = 0.056 at
12 months, P = 0.01 at 18 months) [80]. In the same
series, all cause mortality was strongly associated
with the baseline CAC score, and was signiﬁcantly
lower in the Sevelamer arm after 4.5 years of follow
up (P = 0.02) [71]. Even more surprisingly mortality
was extremely low (3.9%/year) in patients with 0
calcium score. This stands in contrast with a reported
mortality of * 20–25%/year in patients undergoing
hemodialysis. CAC scores were also shown to be
predictive of an unfavorable outcome in dialysis
patients by Matsuoka et al. [81]. The authors
followed 104 chronic hemodialysis patients for an
average of 43 months after a screening EBT. Patients
were divided in two groups according to a baseline
CAC score falling below or above the median for the
group (score = 200). The 5-year cumulative survival
was signiﬁcantly lower for patients with a CAC
score[200 than for those with a score\200
(67.9% vs. 84.2% P = 0.0003).
Summary
CAC appears to be predictive of an adverse outcome
in CKD patients and its absence has been linked with
a very low event rate.
The value of the ZERO calcium
score—ASYMPTOMATIC PATIENTS
The presence of coronary calciﬁcation is, especially
with advancing age, a sensitive but unspeciﬁc ﬁnding.
As discussed above, many studies have emphasized
the graded increase in CHD risk with increasing
calcium scores. However, an even more clinically
relevant ﬁnding may be the absence of CAC. In a
large population of over 10,000 individuals screened
for CAC, all-cause mortality was assessed during a 5-
year follow-up period. With a zero or very low (\10)
calcium score, the investigators reported a very low
probability of mortality, * 1.0% at the end of
follow-up [82]. This ﬁnding was conﬁrmed in a
study by Budoff in 25,253 individuals, in which only
0.4% of the individuals with a negative calcium score
died during almost 7 years of follow-up, compared to
3.3% of individuals with a positive CAC score [57].
In prospective studies in which CHD was used as
outcome measure, a zero or very low calcium score
was associated with a very low probability of events
during follow-up [21, 23, 24, 36, 83]. Church et al.
reported a relative risk of coronary events in subjects
without CAC compared to those with a positive
calcium score of 0.13 (95% CI, 0.06–0.30) [83].
Cumulative incidences in studies with a follow-up
period of 3–5 years ranged between 0.1% and 0.7%
(Table 2). One study showed a somewhat higher
cumulative incidence of 4.4% during more than
6 years [20]. This may be partly explained by the
different CT protocol (6 mm slicing) which may have
resulted in missing calciﬁed lesions.
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123Four studies have speciﬁcally compared the prog-
nosis for men and women in the absence of CAC.
Raggi et al. found no difference in all-cause mortality
after 5 years of follow-up in over 4,000 women and
over 6,000 men with a very low CAC score (\10):
1.6% vs. 1.5% [84]. Recently, the results from three
studies in which CHD was the outcome [21–23], were
used in a meta-analysis [85]. In total, the analysis
included 3,862 women and 5,548 men with absent or
minimal CAC. The annual CHD event rate was very
similar in women and men: 0.2% vs. 0.3%. When
only women and men with no CAC were studied,
rates were somewhat lower (0.16% vs. 0.27%) but
again not signiﬁcantly different. Thus, absent or very
low CAC score carries the same prognostic value in
both genders.
Interestingly, even in the presence of cardiovas-
cular risk factors, the negative predictive value of
absent or minimal CAC appears to be very high. In
the aforementioned study in which all cause mortality
was the outcome [82], further investigations were
performed according to smoking status and diabetes
status of the participants [42, 67]. Absence of CAC
was noted in about 30% of individuals with diabetes,
and in 50% of smokers. Little or no CAC was
associated with a near 100% survival in non-smokers
as well as smokers, and non-diabetic as well as
diabetic subjects.
As discussed in the previous section, Block et al.
[71] reported a very low mortality rate for hemod-
ialysis patients without evidence of CAC (3.9%/
year); this is in contrast with the extremely high
mortality rate (* 25–30%/yearly), typically quoted
for this category of patients. Thus, the absence of
CAC may be an important modiﬁer of the risk of
events even in the presence of cardiovascular risk
factors. The high negative predictive value of a
zero CAC score is extremely valuable, considering
that a large number of asymptomatic individuals
have no CAC. In various studies, absence of CAC
was noted in 26–92% of individuals, depending on
the age of the individuals. Hence, a zero CAC
score may have important implications in daily
clinical practice and on a population level. The
most important question from a population and
societal point of view is whether individuals
without CAC should be considered at low risk,
even in the presence of cardiovascular risk factors,
and therefore be spared therapies such as aspirin
and cholesterol-lowering medications. Although the
current evidence is substantial, such a notion
cannot be endorsed at this time in the absence of
prospective, randomized trials.
The value of ZERO calcium
score—SYMPTOMATIC PATIENTS
Calcium score and prediction of obstructive
coronary artery disease on angiography
As outlined above, a negative CAC score has a
high negative predictive value in asymptomatic
patients of both genders and even in patients with
risk factors such as smoking, diabetes or renal
failure. In symptomatic patients where CAD is
suspected, can a zero or a minimal CAC score
(e.g.,\10) be used as a ﬁlter to rule out obstruc-
tive CAD? Several investigators have addressed
this point. Becker et al. studied 1,347 symptomatic
subjects with suspected CAD [86]. Sensitivity,
speciﬁcity and predictive accuracy were calculated
for different calcium thresholds for prediction of
CAD. In 720 (53%) subjects, invasive angiography
revealed a lumen diameter stenosis greater than
50%. Patients with obstructive CAD had signiﬁ-
cantly higher total calcium scores than patients
without CAD (P = 0.001). The overall sensitivity
of any CAC score to predict stenosis was 99%,
with a speciﬁcity of 32%. An absolute score
cutoff C 100 and an age and sex speciﬁc scor-
e[75th percentile were identiﬁed as the cutoff
levels with the highest sensitivities (86–89%) and
lowest false positive rates (20–22%). Absence of
CAC was highly accurate for exclusion of CAD in
subjects older than 50 years (negative predictive
value = 98%). The authors concluded that the
presence of CAC on MDCT in symptomatic
patients is accurate for prediction of obstructive
CAD and that its absence is associated with a high
negative predictive value for exclusion of CAD.
Several other studies investigated the presence of
non-calciﬁed plaques and obstructive lesions in
patients with a low or zero CAC score. Cheng et al.
assessed the presence and severity of non-calciﬁed
coronary plaques on 64-MDCT coronary angiography
in 554 symptomatic patients with low to intermediate
pre-test likelihood for CAD and zero or low CAC
656 Int J Cardiovasc Imaging (2008) 24:645–671
123score (low score: men, score\50; women,
score\10) [87]. The authors intended to elucidate
how well absence of CAC predicts the absence of
obstructive non-calciﬁed coronary artery plaque
(NCAP). Compared with patients with absent CAC,
those with a low CAC score had markedly increased
rates of critical luminal stenoses (8.7% vs. 0.5%,
P\0.001). The authors concluded that in symptom-
atic patients with low to intermediate pre-test
probability of CAD, absence of CAC predicts very
low prevalence of occlusive NCAP. Nonetheless, low
but detectable CAC scores were signiﬁcantly less
reliable in excluding the presence of plaque that at
times could be obstructive.
Leschka et al. recently studied the potential of
using the CAC score to improve the diagnostic
accuracy of MDCT angiography [88]. They evaluated
74 consecutive patients who underwent CAC scoring,
MDCT angiography and invasive angiography. Seg-
ments that were not evaluable on MDCT angiography
were considered to be false-positive. When using
CAC scores of 0 to exclude stenoses and C 400 to
predict stenosis for segments with non-evaluative
segments, the per-patient sensitivity and speciﬁcity
improved from 98% and 87% to 98% and 100%,
respectively. Only the 0 CAC score was found to be
helpful to exclude stenoses as a high CAC score often
corresponds to more than one stenosis in the coronary
artery tree.
In a study by Rubinshtein et al. [89], the severity
of CAD was examined using 64-MDCT angiography
in patients who underwent testing due to chest pain
syndromes and had a zero or low CAC score. Of 668
consecutive patients, 231 had a low score (\100) or
absent CAC. Obstructive CAD was present in 9 of
125 patients (7%) with a 0 CAC score, and in 18 of
106 (17%) with a low score (CAC: 1–100).
Summary
In conclusion, absent CAC seems to be an excellent
ﬁlter for exclusion of obstructive CAD in symptom-
atic patients with intermediate to high pre-test
likelihood of obstructive CAD. A low CAC score,
however, is more controversial as a number of studies
showed that the presence of non-calciﬁed and poten-
tially obstructive lesions is higher in patients with
low CAC scores and symptoms compared to patients
with a score of zero.
The value of zero calcium score to rule out CAD
in symptomatic patients: comparison to treadmill
stress testing and nuclear stress tests
IndiscussingthepotentialvalueofazeroCACscorein
symptomatic patients for a reliable exclusion of CAD,
other non-invasive tests like ECG stress testing or
nuclear stress testing have to be considered. Exercise
stress testing is often used as the initial non-invasive
diagnostic test in symptomatic patients with suspected
obstructive CAD. Positive standard ECG criteria are
quite speciﬁc for obstructive CAD, but there may be a
substantial number of false negative tests, including
patients with severe disease. Also, exercise stress tests
frequently yield equivocal results. Lamont et al.
assessed the value of combining CAC screening with
a stress test to reduce the high false-positive rate seen
with treadmill stress test (TMST) alone [90]. A CAC
score was obtained by EBT in 153 symptomatic
patientswhounderwentcoronaryangiographybecause
ofapositiveTMST.TheTMSTfalse-positive ratewas
27%(41of153).Inthesepatients,aCACscoreofzero
resulted in a negative predictive value of 93%. The
authors concluded that the absence of CAC reliably
identiﬁed patients with a false-positive TMST result.
Raggi et al. [44] showed that in symptomatic patients
with low to intermediate pretest probability of disease
(5-50%), a CAC score of zero can be reliably used to
exclude obstructive CAD and that calcium scoring as
the initial testto investigate presence ofCAD provides
a substantial cost beneﬁt over a pathway based on
exercisestresstesting.Bermanet al.[40]describedthe
relationship between stress-induced myocardial ische-
mia on single-photon emission computed tomography
(SPECT) perfusion studies and CAC. Including a total
of 1,195 patients without known CAD, 51% asymp-
tomatic, the frequency of ischemia by SPECT was
compared to the magnitude of CAC. The frequency of
ischemic SPECT was\2% with CAC scores\100
and increased progressively with CAC[100 (P for
trend\0.0001). Patients with symptoms and CAC
scores[400 had higher likelihood of myocardial
ischemia versus those without symptoms (P\0.025).
The authors concluded that ischemic SPECT is asso-
ciated with a high likelihood of subclinical
atherosclerosis by CAC, but it is rarely seen for CAC
scores\100.Inmostpatients,lowCACscoresappear
to obviate the need for subsequent non-invasive
testing. Patients with normal perfusion studies,
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123however, frequently had extensive non-obstructive
atherosclerosis by CAC criteria.
Geluket al.determinedtheefﬁciencyofascreening
protocol based onCAC scores comparedwith exercise
testing in patients with suspected CAD, a normal ECG
and troponin levels [43]. A total of 304 patients were
enrolled in a screening protocol that included CAC
scoringbyEBT,andexercisetesting.Decision-making
was based on CAC scores. When the CAC score
was C 400, coronary angiography was recommended.
When the CAC was\10, patients were discharged.
Exercisetestsweregradedaspositive,negativeornon-
diagnostic. The combined endpoint was deﬁned as
coronary event or obstructive CAD at coronary agiog-
raphy. During 12 ± 4 months, CAC C 400, 10–399
and\10 were found in 42, 103 and 159 patients and
thecombinedendpointoccurredin24(57%),14(14%)
and 0 patients (0%), respectively. In 22 patients (7%),
myocardial perfusion scintigraphy was performed
instead of exercise testing due to the inability to
perform an exercise test. A positive, non-diagnostic
and negative exercise test result was found in 37, 76
and 191 patients, and the combined endpoint occurred
in 11 (30%), 15 (20%) and 12 patients (6%), respec-
tively. Receiver–operator characteristics curves
showed that the area under the curve of 0.89 (95%
CI: 0.85–0.93) for CAC was superior to 0.69 (95% CI:
0.61–0.78) for exercise testing (P\0.0001). The
authors concluded that measurement of CAC is an
appropriateinitialscreeningtestinawell-deﬁnedlow-
risk population with suspected CAD.
The value of zero calcium score in patients
presenting with acute chest pain to the emergency
department
The use of CAC assessment was brieﬂy discussed in a
recent consensus paper on the use of MDCT for acute
chest pain [91, 92]. The use of CAC screening has
been described in patients with angina-like symptoms
and negative cardiac enzymes presenting to the
emergency department (ED). Laudon et al. per-
formed CAC scoring in the emergency department
in 104 patients, and noted a negative predictive value
for CAD of 100% for a CAC score of zero [93].
McLaughlin et al. reported a negative predictive
value of 98% in 134 patients in a similar ED setting
[94]. Georgiou et al. followed 198 patients presenting
to the ED with chest pain and normal ECG and
cardiac enzymes and found that the presence of any
CAC is a strong predictor for future cardiac events.
Conversely, patients without CAC may safely be
discharged from the ED given the extremely low rate
of future events (* 0.1%/year) [41]. Nonetheless,
after reviewing the available evidence, Andrews
concluded that currently existing data do not sufﬁ-
ciently support the widespread use of CAC CT in
patients with acute chest pain syndromes [95]. Even
so, in patients at low pre-test likelihood of CAD
presenting with angina-like symptoms to the ED, a
negative CAC score can possibly be used to rule out
an acute coronary syndrome. In conclusion, the
available single center studies based on a limited
number of patients indicate that the negative predic-
tive value of a zero CAC is high ([90%). However,
the positive predictive value is somewhat lower,
rendering CAC screening a highly sensitive, but
poorly speciﬁc modality for the diagnosis of acute
coronary syndromes.
Calcium score progression: interpretation
Serial changes in CAC score may have important
implications for monitoring the response of athero-
sclerotic disease to the initiation of or changes in
plaque-altering medical therapy as well as for iden-
tifying patients with more aggressive disease who are
at high risk for incident CAD [4]. In this section, we
will discuss the methodological approaches to calcu-
lating CAC progression as well as provide a synopsis
of the available literature on the utility of sequential
CT imaging to evaluate atherosclerotic disease
progression.
Serial testing paradigm
Serial testing is based on the concept that changes in
CAC are valid markers of varying atherosclerotic
disease states [96]. Furthermore, a change in CAC
may serve as a surrogate for clinical outcomes or
disease activity and, as such, provides clinically
useful information to guide further patient manage-
ment [97–102]. The paradigm of using imaging as a
surrogate outcome has been advanced in the onco-
logic PET literature [103]. The response evaluation
criteria in solid tumors (RECIST) provide deﬁnable
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of target and non-target lesions.
Using this type of sequential monitoring, a positive
change in CAC score above a given threshold
signiﬁes progressive disease, minimal or no changes
in CAC score identify patients with stable disease,
while a reduction in CAC score beyond a given limit
deﬁnes patients exhibiting regression in their under-
lying disease. With regards to the latter, it is still very
controversial whether CAC truly regresses. As such,
this document will focus on deﬁning rapidly and
slowly progressive disease states.
Reproducibility of CAC CT and its determinants
A major consideration for interpretation of changes in
CAC between serial CT examinations is the variabil-
ity of repeat imaging. Inter-examination variability is
affected by image artifacts including motion, noise,
and partial volume averaging that are highly depen-
dent on the speciﬁc imaging protocol as well as the
extent of CAC burden. Optimal timing of ECG
triggering can reduce variability of Agatston
scores[30 to\15% with EBT [104–106]. The
correlation coefﬁcients across CAC measurements,
including Agatston score (AU), CVS, or MS, are
excellent (r C 0.96, N = 161) [11, 107]. CVS’s
improve reproducibility only marginally compared
to Agatston scores. The square root of the CVS has,
however, been suggested to reduce inter-examination
variability [108].
Differences between types of CT systems are very
small after adjustment for body mass index and CAC
burden [10]. In the MESA study, mean relative
differences between CT examinations at different
times were 20.1% for the Agatston score, and 18.3%
for the interpolated CVS (P\0.01) [10], which are
in line with previous reports. Of note these data were
obtained from CT performed at 80% of the RR-
interval, which is associated with a lower reproduc-
ibility as compared to earlier triggering.
Data acquired with 4-slice CT systems were
reported to have higher rates of mis-registration
compared with EBT [10]. Motion artifacts were also
higher in these CT systems compared to EBT
machines, while image noise was lower [10]. The
reproducibility of the calcium score has improved
with the introduction of 16-slice and more recently
64-slice MDCT systems. The variability is best with
thinner slices, higher calcium scores and with retro-
spective acquisition mode, although this is associated
with a higher radiation dose for the patient. Currently,
the reported variability of the Agatston, volume and
mass score on 16–64-slice MDCT ranges between 8
and 18% (lower end of the range with 64 slice
MDCT) on sequential examinations performed within
minutes of each other [109–111]. Given the radiation
exposure, especially with MDCT systems, the bene-
ﬁt-risk ratio and time intervals of repeat CT must be
considered individually, especially when women and
young men are examined.
Clinical thresholds of coronary artery calcium
progression
Progression of CAC is generally calculated as a
percent or absolute change from the baseline score
using either the Agatston score, CVS, or MS [99, 104,
112–119]. Raggi et al. deﬁned a change[15% as
true progression [98], while Hokanson et al. sug-
gested a CAC progression C 2.5 mm
3 of the square
root of the initial volume score as a useful threshold
of progression [108].
The absolute change in CAC is expected to be
greater in patients with a higher baseline score
(Figs. 3 and 4)[ 98, 115, 116], although the absolute
differences reﬂect minor changes compared to base-
line. Larger percent score changes are expected in
patients with a low index CAC score (e.g., index
CAC score of 10 to repeat score of 20 = progression
of 100%) and do not necessarily reﬂect a clinically
relevant change.
Clinical interpretation of changes in coronary
artery calcium
For most patients within the various risk groups in
Fig. 5, the error in score reproducibility would not
affect their clinical management, unless scores are
close to adjacent risk groups. Variability increases
with CAC score and may be as much as 200–380
units for scores of 400 or higher (Fig. 5)[ 120]. As
scores of 100 or 400 may trigger more aggressive
post-screening management or follow-up ischemia
testing, clinicians should rely less on the absolute
thresholds and more on a combination of CAC score
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risk factor proﬁle. Aggressive management is indi-
cated for scores of 1,000 or higher (very high risk
CAC) and it is unlikely that the expected variability
about this point estimate will change clinical care
[99, 104, 112–119].
Rates of coronary artery calcium progression and
its determinants
In subjects at average Framingham risk the annual
CAC progression rates typically range from 20% to
24% per year using either the Agatston or the CVS
[99, 104, 112–119]. Factors that may signiﬁcantly
modify rate of change include the patient’s baseline
CAC score, gender, age, family history of premature
CAD, ethnicity, diabetes and glycemic control, body
mass index, hypertension, and renal insufﬁciency [98,
121–125]. Further, the longer the interval from
baseline to repeat CAC CT, the greater the expected
change [117]. However, the absolute change will be
greater but the relative change may be smaller. The
score does not continue to grow exponentially and the
rate of growth eventually tapers off. Most patients
exhibit a positive change in CAC scores over time
[99, 112–114, 116, 118] although some patients (29–
34%) exhibit no change if they are at low Framing-
ham risk, including women, or have a baseline score
of 0 (38%) [114]. In patients with an initial 0 score, a
repeat CT\5 years after the initial examination may
not be useful for clinical purposes [114].
Results of randomized clinical trials on effect
of statin therapy on coronary artery calcium
progression
A number of observational studies (Table 3) and
randomized clinical trials (Fig. 6) have evaluated
change in CAC following treatment with statin
therapy. In four observational reports untreated
patients had an average CAC score progression of
36% [98, 126–128]. By comparison, statin therapy
attenuated changes in CAC scores averaging 13%
(Table 3)[ 98, 126–128].
However, these promising observational data were
contradicted by large randomized clinical trials
showing similar changes in CAC scores following
placebo and/or moderate-intensive statin therapy
(Fig. 6). Except for a preliminary pilot trial [129],
all other randomized trials have failed to conﬁrm the
preliminary observational ﬁndings (Fig. 6). Compar-
ison of intensive versus moderate statin therapy
showed no difference in CAC progression (Fig. 6)
[100, 130]. The lack of an effect in these clinical
trials suggests that a longer observational time period
may be warranted and that statins may reduce cardiac
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[4]. Further, these trials often did not consider or plan
the management of other CV risk factors that may
confound the lack of therapeutic beneﬁt [4]. There are
ongoing trials using CAC as a surrogate where
additional evidence may be put forth on the beneﬁt in
serial imaging [131, 132]. Finally, other treatments
have been tested as far as an effect on CAC
progression. In the Women’s Health Initiative
(WHI), menopausal women between the ages of
50–59 years were randomized to treatment with
conjugated estrogens or placebo [133]. In a sub-study
Studies: N Control:Active Control:Active
p=0.016
-1.0 -0.50 0.0 0.50 1.0
Favors
Rx
Favors
Control
Arad [19] 1,005 563:527 240:192 
abs
p=0.39
Baseline CAC Change / yr
Achenbach [129] 66 155* 25:11 relative
Rate Difference (95% CI)
CAC
AU
CVS
RCTs of Statin Therapy vs. Placebo
RCTs of Moderate vs. Intensive Statin Therapy
Studies: N Moderate:Intensive Moderate:Intensive
p=0.36
Summary Effect
-1.0 -0.50 0.0 0.50 1.0
Favors
Intensive Rx
Favors
Moderate Rx
Schmermund130 366 267:205 31:28 relative
23:38
relative p=0.85
p=0.40
Baseline CAC Change / yr
Raggi100 614 371:434
Rate Difference (95% CI)
CAC
CVS
CVS
5.4% (-7.2% to 17.9%)
*Achenbach – Patients had a Treated and Untreated Time Period. Thus, there is no RCT of
Statin vs. Placebo and no summary effect was calculated. 
Abbreviations: CAC=Coronary Artery Calcium, CVS=Calcium Volume Score, 
AU=Agatston Units, RCT=Randomized Clinical Trial, Yr=Year, 
Fig. 6 Summary meta-
analysis of randomized
control trials (RCT) on the
rffect of Statin therapy (Rx)
on CAC progression
Table 3 Percent yearly progression from observational cohorts of consecutive patient series, with average framingham risk, and
evidence of coronary artery calcium (CAC) on baseline CT
Author Year N Entry criteria Score Testing period
(in years)
Percent change
CAC score/year
a
Budoff et al. [126] 2000 299 Consecutive pts. AU C1 33%
Shemesh et al. [117] 2001 116 Asymptomatic
hypertensive pts.
AU 1, 2, 3 Yr. 1: 18%
Yr 2: 31%
Yr 3: 41%
Sutton-Tyrrell et al. [118] 2001 80 Middle-aged women AU 1.5 11%
Yoon et al. [119] 2002 217 Consecutive subjects AU 2.1 34%
CVS 29%
Raggi et al. [99] 2003 772 Consecutive pts. CVS 2.2 26%
Hsia et al. [115] 2004 94 Healthy post-menopausal
women CAC C 10
AU 3.3 27%
Budoff et al. [113] 2005 177 Post-menopausal pts. AU C1 15%–22%
Rasouli et al. [116] 2005 133 Asymptomatic pts. AU 1.7 17%–22%
Gopal et al. [114] 2006 710 Consecutive pts. w/CAC = 0A U C1 Mean ± sd: 1 ± 3
Median (IQR): 0 (0–0.8)
Becker et al. [112] 2007 277 Post-menopausal women CVS 3.3 18%
Summary data 2,875 AU 20%
CVS 24%
a Mean ± standard deviation (s.d.), Median, interquartile range (IQR) in the Gopal series
Abbreviations: CAC = Coronary Artery Calcium, year = year, AU = Agatston units, CVS = calcium volume score,
s.d. = standard deviation
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123of the WHI, 1,064 women were submitted to CAC
screening after 8.7 years from trial initiation. Women
receiving estrogens showed a lower CAC score
compared those receiving placebo (83.1 vs. 123.1,
P = 0.02).
Cardiovascular prognosis related to coronary
artery calcium progression
Despite the lack of an effect of statins on CAC
progression, several reports have noted that a rapid
change in CAC score is associated with worse clinical
outcomes including incident MI [97, 99]. In one
report of 495 patients, subjects who experienced an
acute MI experienced greater degrees of CAC
progression compared to event-free survivors
(42% ± 23% vs. 17% ± 25%, P\0.0001) [97].
Patients with and without[15%/year change in
CAC score had 66% and 97% MI-free survival,
respectively, at 6 years (P\0.0001). Patients who
exhibited signiﬁcant progression from their index CT
(C 15%/year) and those with baseline CAC
score C 400 had a more rapid presentation to acute
MI occurring at 2–4 years post-testing as compared
to those with CAC scores B 100 with incident MI’s
at over 5 years from baseline testing (P\0.0001).
Thus, the baseline CAC score provides an insight into
not only the expected rate of progression but also the
timeline of conversion to symptomatic CAD.
Summary
The evidence is inconclusive as to what is the most
accurate method to deﬁne CAC progression (percent
versus absolute versus square root change). Further
research is indicated as to documenting meaningful
changes in the various scores. For the patient with an
average FRS, the yearly increase in CAC score is
approximately 15–20%. Absolute changes are greater
in patients whose baseline score exceeds 100. To date,
publishedrandomizedtrialshavefailedtodemonstrate
a beneﬁt of statin therapy to attenuate CAC progres-
sion. Despite this, rapidly increasing CAC scores may
be used to deﬁne higher risk patients. Further insight
into the prognostic implications of serial CT examin-
ations is warranted to further guide optimal patient
management. This writing committee does not recom-
mend the systematic performance of serial CAC
scoring in every patient that has undergone a baseline
CT and is receiving treatment for factors related to
atherosclerosis. An individualized approach to assess
rate of progression in speciﬁc situations may be taken
into consideration.
Standardization of the calcium score measured
using different CT systems
The utilization of CAC scores for outcomes data, risk
stratiﬁcation, and particularly, the serial assessment
of patients over time demands accurate measure-
ments. Accurate measurement of MDCT derived
CAC scores requires implementation of standardized
imaging and quantiﬁcation methods on many differ-
ent types of commercially available MDCT systems.
This formidable goal can be achieved by selecting CT
parameters that fulﬁll minimum requirements for
temporal resolution, spatial resolution, and noise and
by applying a physically meaningful, calibration-
based calcium quantiﬁcation algorithm.
A standard for CAC quantiﬁcation was recently
proposed by the Physics Task Group of the Interna-
tional Consortium on Standardization in Cardiac CT
and is reviewed here [6]. Standardized CT protocols
were developed for six CT models from ﬁve manufac-
turers (Aquilion, Toshiba Medical Systems, Nasu,
Japan; Imatron, Imatron San Francisco, CA; Light-
Speed Plus, General Electric Healthcare, Milwaukee,
Wisconsin; MX8000, Philips Medical Systems, Best,
The Netherlands; Volume Zoom, Siemens Medical
Solutions,Erlangen,Germany;Sensation64,Siemens)
usingananthropomorphiccardiacphantomcontaining
water and calcium inserts and capable of simulating
three patient sizes. Manufacturer recommended pro-
tocols met the minimum requirements for imaging
coronary calcium with MDCT: (1) acquisition of at
least four slices per rotation, (2) rotation time less than
or equal to 0.5 s, (3) ability to reference data acqui-
sition or reconstruction to the ECG signal. Most
protocols were, however, modiﬁed to achieve a target
noise level (20–23 HU) in the water insert for each
phantomsize.Thisprimarilyrequireddeterminationof
CTmodel-andsize-speciﬁcvaluesforthetubecurrent
(mA) or tube-current time product (mAs). Small,
medium, and large anthropomorphic phantoms were
then examined on a total of 10 different CT machines
using these standardized CT protocols.
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package because, although not explicitly evaluated by
the Consortium, differences among scoring packages
are assumed to be non-negligible (but low compared
to other sources of error; see next section). To address
this issue, software manufacturers were asked to
modify existing algorithms according to recommen-
dations of the Consortium. Software packages will
then be validated as they become available (at least
three manufacturers have incorporated the Consor-
tium recommendations into their software at this
writing).
To quantify CAC, voxels containing calcium were
ﬁrst isolated from other tissue and image noise
primarily by applying a standard 130 HU attenuation
threshold to the reconstructed images. Agatston,
volume, and mass scores were then calculated using
standard quantiﬁcation algorithms [6]. To obtain
absolute values for calcium mass, a calibration
measurement of a calciﬁcation with known hydroxy-
apatite (HA) density was carried out and a calibration
factor determined. Because the CT number of all
materials except water depends on the X-ray spec-
trum, a speciﬁc calibration factor exists for each
machine and each CT protocol. Work by the Physics
Group of the Consortium also showed that patient
size changes the X-ray spectrum and impacts the
value of the calibration factor signiﬁcantly. There-
fore, a unique calibration factor was determined for
each of three broad categories of patient sizes for
each CT model and each CT protocol using the
cardiac phantom’s water and calcium inserts.
The mass score (mij) was then computed as the
product of the appropriate calibration factor (cHA), the
number of voxels containing calcium (Nvoxel), the
volume of one voxel (Vvoxel), and the mean CT
number for each lesion (CTij):
mij ¼ cHA   Nvoxel   Vvoxel   CTij
The total mass score is the sum of the mass of all
individual lesions.
Analysis of the mean and standard deviation of the
calcium scores measured under ideal conditions from
EBCT and MDCT systems demonstrated a coefﬁcient
of variation of 4.0% for Agatston scores, 7.9% for
volume scores, and 4.9% for mass scores. The
accuracy, or exact correspondence between measured
and true values, could not be assessed for Agatston
scores because this score represents only a
mathematical construct and as such cannot be com-
pared to a physical reference standard. However,
calcium volume and mass scores could be compared
to known values from the cardiac phantom. For the
ﬁve MDCT systems, the total calcium mass score was
within ± 5 mg of the total known mass of calcium
HA within the phantom (168.2 mg). The accuracy of
EBT measurement was considerably worse (mean
mass score equaled 182.7 mg). Therefore, the
increased precision of the mass score as compared
with the volume score and the ability to compare the
measured mass score with a known physical standard
motivated the Consortium to endorse the mass score
approach as the preferred method of quantifying
CAC.
Additional data have been collected by the Physics
group towards optimization of the mass score.
Speciﬁcally, the requirements for calculation of a
calibration factor were examined. Variation in the
measured calibration factor from three sizes of the
anthropomorphic cardiac phantom was assessed
across CT machines, time, and patient sizes. Assess-
ment across CT machines, revealed the coefﬁcient of
variation in the calibration factor was small for a
speciﬁc CT manufacturer and CT model (0.13–
1.6%). Subsequent data analysis from the same CT
systems over time has shown slightly higher variation
for measurements made quarterly over a 4-year
period from a single 16-slice CT machine (2.8–
3.2%) and over a 2-year period from a single 64-slice
CT machine (2.5–3.1). The change in phantom (i.e.,
patient size), however, caused a much larger change
in calibration factor both across CT systems (3.8–
5.1%) and over time (3.4–5.0%). Therefore, determi-
nation of a calibration factor for a given CT machine
and patient size from quarterly CT of an anthropo-
morphic phantom should be sufﬁciently stable over
time to permit 3% or less variation in the measure-
ment. It has been suggested that inclusion of a
calibration insert with each patient is necessary for
precise measurement of a calibration factor. How-
ever, this seems unnecessary based on the low
variability in calibration estimation with quarterly
anthropomorphic CT.
Because of the variation in calibration measure-
ments,particularlyacrosspatientsizes,theconsortium
recommended identifying voxels containing calcium
by applying a threshold based on a ﬁxed density or
concentration of calcium HA (100 mg/cc of calcium
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HU) that may not provide a consistent cutoff value
for calcium across examinations.
In summary, the Physics Group demonstrated that
standardized protocols and algorithms can provide
accurate and precise calcium mass scores in phan-
toms independent of MDCT model and phantom
(patient) size through the use of appropriate calibra-
tion factors. Implementation of these protocols
should move the ﬁeld of CAC scoring closer to the
realization of meaningful quantitative comparisons of
CAC scores measured over time within a patient and
across patients even when imaging is performed
using different MDCT models. An obvious output of
the implementation of such standards should be
reduced variability in CAC measurements although
this remains a point of investigation.
The recommendations of the Consortium have
largely been implemented by the CT manufacturers
making adherence to these standardization proce-
dures in clinical CT straightforward. Additional
relatively tasks beyond current practice will, how-
ever, be required including measurement of lateral
skin-to-skin width at mid-liver from an anteroposte-
rior CT radiograph (‘‘scout’’ image) to assess patient
size, selection of appropriate patient-size speciﬁc
mA/mAs to achieve the noise target, and selection of
appropriate patient-size speciﬁc calibration factor to
determine a density-based attenuation threshold and
calculate absolute calcium mass.
The biggest obstacle to widespread use of the mass
score is the paucity of data available for clinical
decision-making. The CAC score is most clinically
meaningful in the context of risk-stratiﬁcation which
requires referencing a patient’s total CAC score to
age- and sex-matched data. A patient is assigned to a
percentile range of risk on the basis of his or her total
CAC score; the percentile range is deﬁned by ﬂexible
thresholds that take into account the independent
effects of age and sex on the amount of total CAC.
Most currently available databases, particularly those
with a signiﬁcant number of patients, contain only
Agatston scores. An MDCT database founded upon
standard protocols using the mass score is therefore
necessary.
Implementation of a standardization procedure for
theacquisitionandanalysisofCACimagespermitsthe
accumulationofscoresfromvariousMDCTsystemsin
a single database. A web-based database has been
developed through the efforts of the Consortium to
allow collection of standardized MDCT patient risk
factor and CAC data (https://clinapps.bio.ri.ccf.org/
cascore/). A sufﬁcient number of patients must be
entered before assignment of a precise percentile
rankingcanbeprovidedtoanindividualpatient.Based
onearlydata,itwasdeterminedthatatotalregistrysize
of 4,000 would be sufﬁcient to estimate the percentile
ranking of future patients in the age range of 45–
70 years. To date, data from over 1,000 patients have
been collected. The Writing Group supports this stan-
dardization procedure and recommends that this
registry be supported.
Inﬂuence of scoring parameter settings of
underlying software algorithms on calcium
scoring
All scoring methods used for the determination of
CAC have a common denominator. This is the
algorithm used to determine which areas above the
thresholdHUvaluearecalciﬁedlesionsandwhichcan
be discarded as noise. To determine this very impor-
tant distinction, common algorithms are used that are
inﬂuenced by a number of different parameter settings
which, as shown by van Ooijen et al. in 50 patients
imaged with EBT, inﬂuence the resulting CAC score
[134]. The most common parameters are the HU
threshold value, the connectivity, the lesion size
threshold and the use of interpolation. Some commer-
cially available software packages provide the user
with the parameter settings and even allow changing
these parameters. Others hide the default settings and
determining the settings used can be very difﬁcult.
Mean variability can be up to 15–16 points for the
Agatston score with the largest inﬂuence coming from
changing the lesion size threshold between 2 and 4
pixels. For the CVS, mean variability can be up to 20–
30 points largely due to the effect of changing the
lesion size threshold between 2 and 4 pixels and from
turning interpolation on and off. It could well be that
the effect of interpolation will be less prominent when
usingMDCTinsteadofEBTbecauseoftheuseofslice
overlap. There are no published data for the mass
scoring method, but since this method also relies on
algorithms to determine what regions are lesions and
whatregions arenot,itislikelythatsimilarresultswill
be found.
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based on the volume or Agatston score, software
parameter settings affect the outcome. Furthermore,
the use of new software versions or other software
packages and the use of data acquired in other
institutes in the follow-up of patients could also affect
the measured progression or regression of CAC
because of different parameter settings. These data
show, therefore, that not only standardization of CT
protocols is obligatory, but CAC scoring parameters
also need to be standardized. Further research is
required to determine whether using phantom data or
test patient datasets can help standardizing settings
across software and help selecting the appropriate
settings of a certain software package when they are
unclear.
Radiation exposure
A broad implementation of CAC screening may be
limited by factors such as cost, patient access and
demonstration of altered medical outcomes. In addi-
tion, risks associated with the use of ionizing
radiation must be taken into account, especially for
younger or female patients or when considering
additional radiological tests such as CT and MPI.
CAC screening delivers a relatively low radiation
dose (effective dose of 0.7 mSv with EBT and 1.0–
4.1 mSv with MDCT) [135], while coronary CT
angiography (outside of the scope of this writing)
delivers somewhat increased levels of radiation dose
(effective dose of 9.4 to 14.8 mSv) [136]. The dose to
any one individual depends both on the imaging
protocol used and the patient’s body habitus. The
radiation exposure provided by CAC screening is
substantially lower than that of MPI studies (effective
dose range of 13–16 mSv), especially those con-
ducted using Thallium–201 or dual isotope
techniques (effective dose of 27.3 mSv) [137]o r
invasive diagnostic coronary catheterization (effec-
tive dose of 3–10 mSv) [138].
Much of our knowledge on the carcinogenic
effects of low doses of radiation (whole body
exposures of 5–150 mSv) derives from follow-up
data on the survivors of the atomic bombings in
Japan. Although quite small, there appears to be an
increase in incidence of cancer in subjects exposed to
low doses of radiation, especially in children—
because of the higher radiation sensitivity and the
longer available time for cancer development after
exposure. Using the linear non-threshold model of
radiation induced risk and the organ speciﬁc risk from
Biological Effects of Ionizing Radiation (BEIR VII)
[139], the data presented by Einstein et al. [140] can
be linearly scaled to predict the lifetime risk of
cancer. Assuming a factor of 10 reduction of dose
from a coronary CTA exam, the lifetime risk of
cancer for a CAC CT in a 50-year-old individual is
0.04% for a man and 0.12% for a woman. To
properly interpret these data, the individual’s com-
plete risk proﬁle must be considered, including the
background risk of cancer incidence in the general
population and any individual-speciﬁc risks such as
diabetes, high blood pressure or a family history of
cancer or heart disease. According to statistics from
the American Cancer Society, the lifetime risk of
cancer at any site is 45% for men and 38% for
women; the respective death rates are 23 and 20%
[141]. Thus, taking into account the patient’s speciﬁc
medical risks, particularly of CAD, and the back-
ground population risks, the additive cancer risk from
a CAC exam is negligible, provided that some beneﬁt
may be gained from the examination. Thus, this
committee of experts does not support the application
of CAC screening to individuals at low risk of CAD,
where medical beneﬁt is not expected. For individ-
uals at intermediate risk of CAD, the small statistical
risk of cancer induction and death is very low relative
to the patient’s complete risk proﬁle. In these
patients, the potential beneﬁt to the patient from
knowledge obtained in the CAC exam greatly
exceeds the small potential risk of cancer and the
use of CAC screening is recommended in several
clinical scenarios.
Further, in contrast to alarming media reports
regarding the risks associated with ionizing radiation,
the radiation biology and epidemiology community is
divided as to the actual degree of risk at the low doses
associated with medical imaging examinations. Con-
sidering the error bars associated with the data from
the Japanese bomb survivors, the difﬁcultly in
transferring risk estimates between population
cohorts and irradiation dose rates and types (high
versus low dose rates, whole body versus partial body
exposures, etc.), and the conﬂicting reports from
medically exposed populations that show no increase
in risk at medical imaging dose levels, it is the ofﬁcial
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123position of the Health Physics Society that meaning-
ful risk estimates are not possible below effective
doses of 100 mSv [142]. Thus, CAC exams, with
effective doses of 1–4 mSv, may be in fact be
associated with no additional risk and hence should
not be avoided when information important to the
patient’s medical management may be obtained.
Conclusions
The writing committee would like to summarize in a
series of conceptual points the evidence discussed
herein as follows.
We know and support the conclusion that:
• CAC is a good predictor of events in Caucasians
and adds incremental prognostic value to risk
factors in intermediate risk populations
• There is signiﬁcant variability between ethnicities
in the prevalence and extent of coronary calcium.
• Absence of CAC is associated with very low
event rates in most risk categories
• Rapid CAC progression is associated with higher
risk of events
• CAC is a strong predictor of events in end stage
renal disease
• A zero calcium score is associated with a very
low prevalence of ischemia on functional stress
testing and obstructive disease on angiography
We are beginning to understand that:
• CAC may have good predictive value in the
elderly, diabetic patients and patients of different
ethnic background
• CAC scores can be used to predict presence of
obstructive CAD but despite a high sensitivity this
tool demonstrates a low speciﬁcity; hence the
main utilization of CAC should be assessment of
risk of cardiovascular events rather than the
detection of severe CAD
We still need to prove that:
• We can alter CAC progression with medical
interventions
• Altering CAC progression with medical interven-
tions impacts patients’ outcome
• We may not need to treat patients with risk factors
in the absence of CAC
Finally, standardized procedures for both image
acquisitionandCACscoringshouldbefollowedsothat
we might best advance our knowledge using MDCT.
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